Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
MORRISVILLE, N.C., Nov. 23, 2016 -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that Nathan Stasko, PhD, President and Chief Executive Officer of Novan, is scheduled to participate in a fireside chat at the Piper Jaffray 28th Annual Healthcare Conference, Tuesday, Nov. 29, 2016, 4:30 p.m. EST, in New York.
The presentation will be webcast live and can be accessed through the Investor Relations section of the Company’s website at www.Novan.com. An archived version of the webcast will be available approximately two hours following the live presentation for 90 days.
About Novan
Novan, Inc. is a late-stage pharmaceutical company focused on redefining the standard of care in dermatology through the development and commercialization of innovative therapies using the Company’s nitric oxide-releasing platform. Nitric oxide plays a vital role in the natural immune system response against microbial pathogens and is a critical regulator of inflammation. Our ability to harness nitric oxide and its multiple mechanisms of action has enabled us to create a platform with the potential to generate differentiated, first-in-class product candidates. We are rapidly advancing programs in five dermatological conditions with significant unmet medical need. We believe that our ability to conveniently deploy nitric oxide on demand in topical formulations allows us the potential to significantly improve patient outcomes in a variety of skin diseases and positions us to be a commercially successful leader in the dermatology market.
For more information, visit the Company’s website at www.Novan.com.
Forward-Looking Statements
This press release contains forward-looking statements including, but not limited to, statements related to pharmaceutical development of nitric oxide-releasing product candidates and future prospects. Forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from our expectations, including risks and uncertainties described in our prospectus dated Sept. 20, 2016, filed with the Securities and Exchange Commission (the “SEC”), in our quarterly report filed with the SEC on Form 10-Q for the three months ended Sept. 30, 2016, and in any subsequent filings with the SEC. These forward-looking statements speak only as of the date of this press release, and Novan disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances after the date of such statements, except as may be required by law.
CONTACT: (Investors) Sean Andrews, Senior Director of Investor Relations Novan, Inc. 919-627-6847 [email protected] (Media) Deb Holliday Pascale Communications, LLC 412-877-4519 [email protected]
